FDA accepts review of long-delayed Merck blood clot drug
July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing ...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/TVFv_9SnsWQ/story01.htm
No comments:
Post a Comment